ZTS Stock Overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$177.72 |
| 52 Week High | US$194.99 |
| 52 Week Low | US$124.15 |
| Beta | 0.77 |
| 1 Month Change | -2.79% |
| 3 Month Change | 4.13% |
| 1 Year Change | 19.60% |
| 3 Year Change | 10.17% |
| 5 Year Change | 93.89% |
| Change since IPO | 473.11% |
Recent News & Updates
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25
Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Recent updates
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Zoetis Is An Awesome Dividend Growth Stock
Jan 17It's A Great Time To Buy Zoetis Shares
Jan 10Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Jan 03Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Dec 29Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Zoetis raises quarterly dividend by 15.4% to $0.375/share
Dec 08Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Nov 20Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth
Nov 08Zoetis Q3 2022 Earnings Preview
Nov 02Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?
Nov 02Zoetis declares $0.325 dividend
Oct 13A Rising Dollar May Mean Lower Zoetis Shares
Oct 07Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Sep 15Zoetis cleared to acquire Jurox in Australia subject to divestiture
Sep 15Zoetis acquires Scottish animal health digital tech business
Sep 05Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 21%?
Aug 19Zoetis: Strong Q2 Underlying Growth But Hit By Strong U.S. Dollar
Aug 12Zoetis Q2 2022 Earnings Preview
Aug 03Zoetis: Lovable Company With Vision
Jul 20Here's Why We Think Zoetis (NYSE:ZTS) Is Well Worth Watching
Jul 04Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Jun 17Zoetis: Animal Health Leader Now Cheapest Since April 2021
May 20An Intrinsic Calculation For Zoetis Inc. (NYSE:ZTS) Suggests It's 21% Undervalued
May 17Why You Might Want To Add Zoetis To Your Portfolio
Apr 13Here's Why I Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Mar 26Zoetis: Upgrade To Buy After 22% Fall From Peak And Strong Q4
Feb 18Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Feb 09Shareholder Returns
| ZTS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.1% | -2.0% | -2.7% |
| 1Y | 19.6% | 11.9% | 16.8% |
Return vs Industry: ZTS exceeded the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: ZTS exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: ZTS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ZTS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 13,800 | Kristin Peck | https://www.zoetis.com |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZTS fundamental statistics | |
|---|---|
| Market Cap | US$81.81b |
| Earnings (TTM) | US$2.21b |
| Revenue (TTM) | US$8.22b |
37.0x
P/E Ratio9.9x
P/S RatioIs ZTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZTS income statement (TTM) | |
|---|---|
| Revenue | US$8.22b |
| Cost of Revenue | US$2.45b |
| Gross Profit | US$5.78b |
| Other Expenses | US$3.56b |
| Earnings | US$2.21b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.81 |
| Gross Margin | 70.24% |
| Net Profit Margin | 26.92% |
| Debt/Equity Ratio | 142.6% |
How did ZTS perform over the long term?
See historical performance and comparison